ED traces Rs 74 crore drug hawala trail, raising UAE pharmacy due-diligence risk

India's Enforcement Directorate (ED) has traced Rs 74 crore in alleged narcotics proceeds sent through hawala channels to Afghanistan, a case that gives UAE pharmacy operators a practical warning on supply-chain checks, controlled-medicine records and suspicious payment patterns.

For Dubai clinics and pharmacies, the highest-value readers are COOs, CFOs and compliance leads. The issue is operational. A foreign investigation does not change UAE medicine prices or licences, but it shows how narcotics, import documentation and informal finance can overlap in a healthcare-adjacent trade route that ED said involved Afghanistan, Pakistan and Dubai.

What ED says happened

LatestLY, carrying an ANI report dated 23 September 2026, said ED's investigation into an international drug smuggling syndicate found that proceeds from illegal narcotic sales were moved to Afghanistan through hawala and allegedly used for terror funding. The report said ED identified total proceeds of crime of Rs 89 crore linked to narcotics trafficking, contraband smuggling, distribution of drug proceeds and hawala operations.

The same ANI account said the National Investigation Agency (NIA) first identified the Rs 74 crore hawala transaction trail, which ED later examined under its money-laundering investigation. Earlier reporting on the case linked the probe to Harpreet Singh Talwar, the accused in the 3,000 kg Mundra Port heroin seizure, and to consignments where heroin was allegedly concealed in semi-processed talc imported from Afghanistan.

Readers can check the source report through the LatestLY item on Google News and ED public updates through the Enforcement Directorate.

Why this matters in Dubai first

Dubai pharmacy operators are regulated by the Dubai Health Authority (DHA), with licensing and facility services handled through Sheryan. DHA lists facility services for controlled and semi-controlled medication transfers, medicine destruction, adverse drug incident reporting and controlled-medicine inventory activation. That is the practical checklist for a Dubai pharmacy board after this case.

The point for CFOs is payment control. Hawala is outside normal banking channels, so any pharmacy, wholesaler or clinic buying medical products should be able to match invoices, bank payments, import documents, batch numbers and dispensing records. A cash discount on a medicine order is a finance issue before it becomes a legal issue.

COOs should ask four questions this week:

• Can every controlled or semi-controlled medicine stock movement be reconciled to an approved electronic record?
• Are supplier trade licences, pharmacy licences and responsible pharmacist details current for 2026?
• Do payment records exclude cash settlement, third-party settlement and offshore settlement outside approved contracts?
• Can staff identify when a patient needs a controlled-medicine prescription rather than an ordinary medicine request?

Patients have a narrower action point. Buy prescription medicines only from licensed pharmacies, and check whether imported personal medicines fall under UAE controlled-medicine rules. The UAE government portal states that narcotic, psychotropic and other controlled medicines of class A or B are not freely available or freely imported into the UAE.

Abu Dhabi, northern emirates and payer exposure

In Abu Dhabi and Al Ain, the relevant regulator is the Department of Health Abu Dhabi (DOH). DOH issued a circular activating the inventory management module of the National Platform for Prescribing and Dispensing Narcotic and Controlled Medications in Abu Dhabi from 15 July 2024. In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, pharmacy licensing and medicine controls sit with the Ministry of Health and Prevention (MOHAP) and, for transferred drug services, the Emirates Drug Establishment (EDE).

Insurers such as Daman, Thiqa and Sukoon should treat this as a claims-pattern story, not a foreign crime brief. Red flags include repeated controlled-medicine claims from the same prescriber, high-frequency pharmacy switching, diagnosis codes that do not support the medicine, and reimbursement claims where the dispensing pharmacy cannot provide the required record trail.

There is no defensible AED price range to derive from the ED case. UAE operators should use official medicine price files rather than supplier quotes in isolation. MOHAP's registered medications list, EDE services and DHA price-list requirements are the safer reference points for retail checks and internal audit files.

The practical close is simple. Before adding a pharmacy partner, supplier or delivery channel, verify the licence against an official UAE register and review the controlled-medicine process. The UAE Open Healthcare Directory lists more than 3,898 pharmacy providers and anchors facility records to DHA Sheryan, DOH datasets and MOHAP registers for licensed-provider checks.